May 28, 2021
6 min watch
Save
VIDEO: New data on dupilumab in children with uncontrolled moderate to severe asthma
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Leonard B. Bacharier, MD, presents results of the LIBERTY ASTHMA VOYAGE trial, which evaluated dupilumab in children aged 6 to 11 years with uncontrolled moderate to severe asthma with evidence of type 2 inflammation.
Dupilumab (Dupixent, Sanofi/Regeneron) significantly reduced asthma exacerbations and improved lung function within 2 weeks, Bacharier, professor of pediatrics at Monroe Carroll Jr. Children’s Hospital at Vanderbilt University, told Healio.
Read more about the study here.